默沙东宣布Enflonsia®获加拿大卫生部批准 用于新生儿及婴儿呼吸道合胞病毒预防

美股速递
Feb 05

默沙东(Merck)近日宣布,其创新药物Enflonsia®已正式获得加拿大卫生部批准,该药物专门用于新生儿和婴儿群体的呼吸道合胞病毒(RSV)预防。此次获批标志着默沙东在儿科疾病防控领域取得重要进展,为婴幼儿健康提供了新的防护方案。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10